Ask AI

Resolving Unmet Needs in CMVi: Contemporary Strategies for Improved HCT Outcomes

Cytomegalovirus infection (CMVi) remains a major source of morbidity and mortality in hematopoietic cell transplant (HCT) recipients. With these activities, learn to effectively identify and monitor high-risk patients, individualize treatment to minimize adverse effects, and optimize therapy for treatment-refractory CMV in post-HCT settings. 

Share

Program Content

Activities

Contemporary CMV Management Slides
Optimizing Transplant Outcomes Through Contemporary CMV Management: Strategies to Address Clinical Challenges in Treatment of Refractory or Resistant Disease
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2026

Activities

Treatment of CMV in HCT Recipients
The Burden and Treatment of CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 17, 2026

Expires: February 16, 2027

Treatment of Refractory Resistant CMV
Treatment of Refractory/Resistant CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 18, 2026

Expires: February 17, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.